FIELD: biotechnology.
SUBSTANCE: invention relates to a method of changing target DNA in a cell in vitro. This method involves providing the cell with the Cas enzyme of the CRISPR type II system, which forms a colocalization complex with a guide RNA complementary to the target DNA, and which cleaves the target DNA in a site-specific manner, introducing into the cell a guide RNA that is complementary to the target DNA and which directs a CRISPR type II Cas enzyme to a target DNA, where the guide RNA and a CRISPR type II Cas enzyme are members of a colocalization complex for the target DNA, and introducing a donor nucleic acid sequence into the cell, where the guide RNA and the donor nucleic acid sequence are linked.
EFFECT: invention is effective for changing target DNA in a cell in vitro.
18 cl, 20 dwg, 6 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GENOMIC ENGINEERING | 2014 |
|
RU2764757C2 |
| RNA-GUIDED TRANSCRIPTION REGULATION | 2014 |
|
RU2756865C2 |
| DELIVERY, CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND USE IN THERAPY | 2013 |
|
RU2721275C2 |
| COMPONENTS OF THE CRISPR-CAS SYSTEM, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | 2013 |
|
RU2796549C2 |
| RNA-GUIDED HUMAN GENOME ENGINEERING | 2013 |
|
RU2766685C2 |
| SYSTEM DESIGN, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR SEQUENCE MANIPULATION | 2013 |
|
RU2796017C2 |
| NEW ENZYMES AND CRISPR SYSTEMS | 2016 |
|
RU2777988C2 |
| NEW CRISPR ENZYMES AND SYSTEMS | 2016 |
|
RU2771826C2 |
| CRISPR ENZYME MUTATIONS REDUCING NON-TARGETED EFFECTS | 2016 |
|
RU2752834C2 |
| TECHNOLOGY FOR CREATING T-CELL RESISTANCE TO HIV-1 BASED ON GENETICALLY ENCODED GPI-ANCHORED PEPTIDES FROM GP41 | 2020 |
|
RU2769567C1 |
